Olopatadine 0.1% and 0.2% ophthalmic solution for the management of ocular allergy

References

• Abelson MB, Smith L, Chapin M. Ocular allergic disease: mechanisms, disease sub-types, treatment. Ocul. Surf.1(3), 127–149 (2003).
   PubMedGoogle Scholar
• Phipatanakul W. Allergic rhinoconjunctivitis: epidemiology. Immunol. Allergy Clin. North Am.25(2), 263–281 (2005).
   PubMed Web of Science ®Google Scholar
• McGill JI. A review of the use of olopatadine in allergic conjunctivitis. Int. Ophthalmol.25(3), 171–179 (2004).
   PubMedGoogle Scholar
• Leonardi A, Motterle L, Bortolotti M. Allergy and the eye. Clin. Exp. Immunol.153(1), 17–21 (2008).
   PubMed Web of Science ®Google Scholar
• McGill J. Conjunctival cytokines in ocular allergy. Clin. Exp. Allergy30(10), 1355–1357 (2000).
   PubMed Web of Science ®Google Scholar
• McGill JI, Holgate ST, Church MK, Anderson DF, Bacon A. Allergic eye disease mechanisms. Br. J. Ophthalmol.82(10), 1203–1214 (1998).
   PubMed Web of Science ®Google Scholar
• Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J. Allergy Clin. Immunol.115(1), 118–122 (2005).
   PubMed Web of Science ®Google Scholar
• Bacon AS, Ahluwalia P, Irani AM et al. Tear and conjunctival changes during the allergen-induced early- and late-phase responses. J. Allergy Clin. Immunol.106(5), 948–954 (2000).
   PubMed Web of Science ®Google Scholar
• Bonini S, Bonini S, Vecchione A, Naim DM, Allansmith MR, Balsano F. Inflammatory changes in conjunctival scrapings after allergen challenge in humans. J. Allergy Clin. Immunol.82(3 Pt 1), 462–466 (1988).
   PubMed Web of Science ®Google Scholar
• Leonardi A, Curnow SJ, Zhan H, Calder VL. Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin. Exp. Allergy36(6), 777–784 (2006).
   PubMed Web of Science ®Google Scholar
• Anderson DF, MacLeod JD, Baddeley SM et al. Seasonal allergic conjunctivitis is accompanied by increased mast cell numbers in the absence of leukocyte infiltration. Clin. Exp. Allergy27(9), 1060–1066 (1997).
   PubMed Web of Science ®Google Scholar
• Irani AM, Butrus SI, Tabbara KF, Schwartz LB. Human conjunctival mast cells: distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis. J. Allergy Clin. Immunol.86(1), 34–40 (1990).
   PubMed Web of Science ®Google Scholar
• Miller S, Cook E, Graziano F, Spellman J, Yanni J. Human conjunctival mast cell responses in vitro to various secretagogues. Ocul. Immunol. Inflamm.39(2), 39–49 (1996).
   Google Scholar
• Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB. Two types of human mast cells that have distinct neutral protease compositions. Proc. Natl Acad. Sci. USA83(12), 4464–4468 (1986).
   PubMed Web of Science ®Google Scholar
• Anderson DF, Zhang S, Bradding P, McGill JI, Holgate ST, Roche WR. The relative contribution of mast cell subsets to conjunctival TH2 cytokines. Invest. Ophthalmol. Vis. Sci.42(5), 995–1001 (2001).
   PubMed Web of Science ®Google Scholar
• Cook EB, Stahl JL, Miller ST et al. Isolation of human conjunctival mast cells and epithelial cells: tumor necrosis factor-a from mast cells affects intercellular adhesion molecule 1 expression on epithelial cells. Invest. Ophthalmol. Vis. Sci.39(2), 336–343 (1998).
   PubMed Web of Science ®Google Scholar
• Ohmori K, Hayashi K, Kaise T et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J. Pharmacol.88(4), 379–397 (2002).
   PubMedGoogle Scholar
• Abelson MB. A review of olopatadine for the treatment of ocular allergy. Expert Opin. Pharmacother.5(9), 1979–1994 (2004).
   PubMed Web of Science ®Google Scholar
• Ohmori K, Hasegawa K, Tamura T et al. Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneimittelforschung54(12), 809–829 (2004).
   PubMed Web of Science ®Google Scholar
• Sharif NA, Xu SX, Yanni JM. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J. Ocul. Pharmacol. Ther.12(4), 401–407 (1996).
   PubMed Web of Science ®Google Scholar
• Sharif NA, Xu SX, Miller ST, Gamache DA, Yanni JM. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J. Pharmacol. Exp. Ther.278(3), 1252–1261 (1996).
   PubMed Web of Science ®Google Scholar
• Yanni JM, Miller ST, Gamache DA, Spellman JM, Xu S, Sharif NA. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann. Allergy Asthma Immunol.79(6), 541–545 (1997).
   PubMed Web of Science ®Google Scholar
• Yanni JM, Stephens DJ, Miller ST et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J. Ocul. Pharmacol. Ther.12(4), 389–400 (1996).
   PubMed Web of Science ®Google Scholar
• Brockman H, Graff G, Spellman J, Yanni J. A comparison of the effects of olopatadine and ketotifen on model membranes. Acta Ophthalmol. Scand. Suppl.230, 10–15 (2000).
   Google Scholar
• Brockman HL, Momsen MM, Knudtson JR, Miller ST, Graff G, Yanni JM. Interactions of olopatadine and selected antihistamines with model and natural membranes. Ocul. Immunol. Inflamm.11(4), 247–268 (2003).
   PubMed Web of Science ®Google Scholar
• Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells. Ann. Allergy Asthma Immunol.87(5), 424–429 (2001).
   PubMed Web of Science ®Google Scholar
• Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits TNF-α release from human conjunctival mast cells. Ann. Allergy Asthma Immunol.84(5), 504–508 (2000).
   PubMed Web of Science ®Google Scholar
• Kajita J, Inano K, Fuse E, Kuwabara T, Kobayashi H. Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities. Drug Metab. Dispos.30(12), 1504–1511 (2002).
   PubMed Web of Science ®Google Scholar
• Nonaka H, Otaki S, Ohshima E et al. Unique binding pocket for KW-4679 in the histamine H1 receptor. Eur. J. Pharmacol.345(1), 111–117 (1998).
   PubMed Web of Science ®Google Scholar
• Yanni JM, Weimer LK, Sharif NA, Xu SX, Gamache DA, Spellman JM. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch. Ophthalmol.117(5), 643–647 (1999).
   PubMed Web of Science ®Google Scholar
• Yanni JM, Sharif NA, Gamache DA, Miller ST, Weimer LK, Spellman JM. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs. Acta Ophthalmol. Scand.77(228), 33–37 (1999).
   PubMedGoogle Scholar
• Kishimoto K, Kaneko S, Ohmori K, Tamura T, Hasegawa K. Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein. Mediators Inflamm.2006(1), 42726 (2006).
   PubMedGoogle Scholar
• Lekhanont K, Park CY, Combs JC, Suwan-Apichon O, Rangsin R, Chuck RS. Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye. J. Ocul. Pharmacol. Ther.23(1), 83–88 (2007).
   PubMed Web of Science ®Google Scholar
• Villareal AL, Farley W, Pflugfelder SC. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Eye Contact Lens32(6), 272–276 (2006).
   PubMedGoogle Scholar
• Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch. Ophthalmol.108(1), 84–88 (1990).
   PubMed Web of Science ®Google Scholar
• Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am. J. Ophthalmol.125(6), 797–804 (1998).
   PubMed Web of Science ®Google Scholar
• Leonardi AA, Abelson MB. Double-masked, randomized, placebo-controlled controlled clinical study of the mast cell stabilizing effect of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin. Ther.25(10), 2539–2552 (2003).
   PubMed Web of Science ®Google Scholar
• Abelson MB, Pratt S, Mussoline JF, Townsend D. One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with contralateral use of olopatadine and artificial tears. Clin. Ther.25(7), 2070–2084 (2003).
   PubMed Web of Science ®Google Scholar
• Deschenes J, Discepola M, Abelson MB. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. Acta Ophthalmol. Scand. Suppl.228, 47–52 (1999).
   Google Scholar
• Butrus S, Greiner JV, Discepola M, Finegold I. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin. Ther.22(12), 1462–1472 (2000).
   PubMed Web of Science ®Google Scholar
• Berdy GJ, Spangler DL, Bensch G, Berdy SS, Brusatti RC. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival allergen challenge model. Clin. Ther.22(7), 826–833 (2000).
   PubMed Web of Science ®Google Scholar
• Leonardi A, Zafirakis P. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked environmental study of patient preference. Curr. Med. Res. Opin.20(8), 1167–1173 (2004).
   PubMed Web of Science ®Google Scholar
• Berdy GJ, Stoppel JO, Epstein AB. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model. Clin. Ther.24(6), 918–929 (2002).
   PubMed Web of Science ®Google Scholar
• Spangler DL, Bensch G, Berdy GJ. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.5% ophthalmic solution in the conjunctival allergen challenge model. Clin. Ther.23(8), 1272–1280 (2001).
   PubMed Web of Science ®Google Scholar
• Brubaker K, Wright RC, Yerxa BR, Bayer JL. In vitro analysis of antagonism of the histamine H1 receptor by epinastine: a kinetic comparison with other marketed compounds. Presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Fort Lauderdale, FL, USA, 30 April–4 May 2006 (Abstract 4975).
   Google Scholar
• Lanier BQ, Finegold I, D’Arienzo P, Granet D, Epstein AB, Ledgerwood GL. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival challenge model. Curr. Med. Res. Opin.20(8), 1227–1233 (2004).
   PubMed Web of Science ®Google Scholar
• Finegold I, Granet DB, D’Arienzo PA, Epstein AB. Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study. Clin. Ther.28(10), 1630–1638 (2006).
   PubMed Web of Science ®Google Scholar
• Sumi T, Fukushima A, Sawada K et al. Evaluation of 0.1% olopatadine hydrochloride ophthalmic solution for allergic conjunctivitis. Rinsho Ganka62, 313–317 (2008).
   Google Scholar
• Yaylali V, Demirlenk I, Tatlipinar S et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol. Scand.81(4), 378–382 (2003).
   PubMedGoogle Scholar
• Aguilar AJ. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta Ophthalmol. Scand. Suppl.230, 52–55 (2000).
   PubMedGoogle Scholar
• Avunduk AM, Tekelioglu Y, Turk A, Akyol N. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Clin. Ther.27(9), 1392–1402 (2005).
   PubMed Web of Science ®Google Scholar
• Borazan M, Karalezli A, Akova YA, Akman A, Kiyici H, Erbek SS. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Acta Ophthalmol.87(5), 549–554 (2009).
   PubMed Web of Science ®Google Scholar
• Dogru M, Ozmen A, Ertürk H, Sanli O, Karatas A. Changes in tear function and the ocular surface after topical olopatadine treatment for allergic conjunctivitis: an open-label study. Clin. Ther.24(8), 1309–1321 (2002).
   PubMed Web of Science ®Google Scholar
• Abelson MB, Torkildsen GL, Williams JI, Gow JA, Gomes PJ, McNamara TR; Bepotastine Besilate Ophthalmic Solutions Clinical Study Group. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a Phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. Clin. Ther.31(9), 1908–1921 (2009).
   PubMed Web of Science ®Google Scholar
• Uchio E. Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops. Clin. Ophthalmol.2(3), 525–531 (2008).
   PubMedGoogle Scholar
• Rosenwasser LJ, O’Brien T, Weyne J. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research. Curr. Med. Res. Opin.21(9), 1377–1387 (2005).
   PubMed Web of Science ®Google Scholar
• Lee JS, Lee JE, Kim N, Oum BS. Comparison of the conjunctival toxicity of topical ocular antiallergic agents. J. Ocul. Pharmacol. Ther.24(6), 557–562 (2008).
   PubMed Web of Science ®Google Scholar
• Khoh-Reiter S, Jessen BA. Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model. BMC Ophthalmol.28(9), 5 (2009).
   Google Scholar
• Lambiase A, Micera A, Bonini S. Multiple action agents and the eye: do they really stabilize mast cells?. Curr. Opin. Allergy Clin. Immunol.9(5), 454–465 (2009).
   PubMed Web of Science ®Google Scholar
• Abelson MB, Gomes PJ. Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing. Expert Opin. Drug Metab. Toxicol.4(4), 453–461 (2008).
   PubMed Web of Science ®Google Scholar
• Vogelson CT, Abelson MB, Pasquine T et al. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration. Allergy Asthma Proc.25(1), 69–75 (2004).
   PubMed Web of Science ®Google Scholar
• Abelson MB, Gomes PJ, Pasquine T, Edwards MR, Gross RD, Robertson SM. Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis. Allergy Asthma Proc.28(4), 427–433 (2007).
   PubMed Web of Science ®Google Scholar
• Abelson MB, Spangler DL, Epstein AB, Mah FS, Crampton HJ. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge. Curr. Eye Res.32(12), 1017–1022 (2007).
   PubMed Web of Science ®Google Scholar
• Lichtenstein SJ, Pasquine TA, Edwards MR, Wells DT, Gross RD, Robertson SM. Safety and tolerability of olopatadine 0.2% in children and adolescents. J. Ocul. Pharmacol. Ther.23(4), 366–371 (2007).
   PubMed Web of Science ®Google Scholar
• Mah FS, Rosenwasser LJ, Townsend WD, Greiner JV, Bensch G. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge. Curr. Med. Res. Opin.23(6), 1445–1452 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenwasser LJ, Mahr T, Abelson MB, Gomes PJ, Kennedy K. A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis. Allergy Asthma Proc.29(6), 644–653 (2008).
   PubMed Web of Science ®Google Scholar
• Scoper SV, Berdy GJ, Lichtenstein SJ et al. Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis. Adv. Ther.24(6), 1221–1232 (2007).
   PubMed Web of Science ®Google Scholar
• Mah FS, O’Brien T, Kim T, Torkildsen G. Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye. Curr. Med. Res. Opin.24(2), 441–447 (2008).
   PubMed Web of Science ®Google Scholar